It’s been 40 years since a truly novel drug has been approved for brain disorders – largely because the standard, target-based approach adopted by biopharma has proven ineffective against CNS dysfunction.
We recognized this industry-wide problem, and did something about it. We embarked on a radically different, unbiased approach – validated and funded by the NIMH – to build a robust pipeline of clinical programs to treat brain disorders, giving hope to millions of patients and their families who suffer every day.
The prevailing approach used by pharma to identify CNS targets is flawed and highly ineffective. Instead of merely tweaking current strategies, we’re coming at it from an entirely new angle for greater efficiency and efficacy.
By using an unbiased approach to systems neuroscience, we examine the entire brain circuitry rather than simply a single drug target, allowing the system to reveal what’s useful.
Our flexible, privileged chemistry platform can be applied to multiple CNS indications and is highly effective at identifying drug-like compounds, leading to efficient design.
Together with our AI partners, Exscientia and PsychoGenics, we optimize desirable small molecules for normalizing the behavioral symptoms of brain disorders.
Our approach has received clinical validation through R&D we've pioneered over the past 15 years. Our first pre-clinical candidate is for bipolar depression, with additional programs for treatment-resistant depression, schizophrenia, and geriatric psychosis.
VIEW FULL PIPELINE
Our founders, Thomas Large and Kerry Spear, are internationally-recognized experts in translational medicine, neuropharmacology and medicinal chemistry. Both have held leadership roles at leading pharmaceutical companies like Eli Lilly and Sunovion.
MEET THE TEAMBlue Oak has received sustained funding from the National Institute of Mental Health (NIMH) to support drug discovery and clinical development.
For investment or partnership opportunities or to learn more about our clinical programs, contact our team today.
Contact us
